Ranbaxy Abused 'First-To-File' For Heartburn Treatment: Suit
Defunct Indian pharmaceutical company Ranbaxy Laboratories Ltd. lied to the U.S. Food and Drug Administration and unfairly blocked other generic forms of the heartburn treatment Nexium in order to gain "first-to-file"...To view the full article, register now.
Already a subscriber? Click here to view full article